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A systematic search was conducted for the time period April 1 2013 to March 30 2014 using PubMed to
identify major osteoarthritis (OA) clinical research themes of the past year. Articles within each theme
were selected for inclusion in this review based on study quality and relevance. Two major themes
emerged, which relate to the current understanding of OA as a heterogeneous condition with multiple
pathogenic mechanisms and clinical manifestations. Theme 1 stems from the role of systemic inﬂam-
mation in OA pathogenesis, and the concept of ‘metabolic OA’. Over the past year, research has examined
the effect of OA on incidence and progression of other ‘metabolic syndrome’-related conditions, espe-
cially cardiovascular disease (CVD) and diabetes and the impact of multi-morbidity on the clinical
management of OA. Theme 2 focuses on the concept of personalized medicine as it relates to the
treatment of OA. It is hypothesized that the modest efﬁcacy of available OA treatments is a result of
inclusion of heterogeneous groups of OA patients in clinical trials. Prognostic studies in the past year
have been helpful in identifying ‘OA phenotypes’ that are more or less likely to respond to treatments e
e.g., the presence of synovitis on imaging, central pain sensitization on quantitative sensory testing
(QST), or coping efﬁcacy by self-reported patient questionnaire. Their ﬁndings are being increasingly
used to target interventions to these identiﬁed ‘OA responder’ subgroups with the hopes that treatment
effect will be ampliﬁed.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
It is now generally understood that osteoarthritis (OA), is a
heterogeneous condition that develops as a result of the effects of
local (joint level) factors, e.g., abnormal gait biomechanics, and
systemic factors, e.g., aging, genetics, and systemic inﬂammation
related to obesity. Adipose tissue produces inﬂammatory adipo-
kines that have the potential to inﬂuence all synovial joint tissues,
which has given rise to the term ‘metabolic OA’1,2. Given shared risk
factors e aging and obesity e there is also growing appreciation of
the fact that most people living with OA are also living other
chronic conditions, including hypertension3,4, dyslipidemia5, dia-
betes6, and cardiovascular disease (CVD)7. It is estimated that 90% of
individuals aged 65þ years with OA have at least one other chronic
condition8. This is concerning as comorbidity in OA has been linked
signiﬁcantly and independently to under-use of effectiveG.A. Hawker, Department of
t, Suite RFE 3-805, Toronto,
23-7513.
gillian.hawker@wchospital.ca
ternational. Published by Elsevier Ltherapies9e13. Without effective treatment, people with OA tend to
give up activities, like exercise, that exacerbate their symptoms10,14.
This has led researchers over the past year to hypothesize that, by
limiting physical activity, painful OA may increase the risk for CVD
and all-cause death. Indeed, in 2011 Nuesch et al.15 reported in a
cohort aged 35þ years with hip and knee OA recruited 1994e1995
from 40 English general practices (n ¼ 2703), and after controlling
for confounders, that baseline walking disability predicted
increased all-cause death (1.48, 1.17e1.86), especially from CVD
causes. Given the high prevalence of OA in the population, conﬁr-
mation of these relationships is important.
Recognition that OA it not so much a single entity but the ﬁnal
common pathway of a variety of conditions with distinct causes
(genetic, developmental, metabolic, traumatic), but with similar
biologic, morphologic and clinical outcomes, has led to a paradigm
shift in howwe think about treatment for this condition. The failure
of clinical trials to date to identify highly efﬁcacious therapies in OA
may be due to true lack of such therapies or the conduct of trials in
heterogeneous groups of OA patientse that is, in groups of patients
that include both potential ‘responders’ and ‘non-responders’16.
Stratiﬁcation of patients into subgroups based on their likelihood of
response to the treatment of interest has potential to improve thetd. All rights reserved.
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spurred interest in identifying predictors of response to available
and new OA therapies which may inform patientephysician deci-
sion making about treatment options.
With this background, this review sought to highlight studies
published over the prior year, since the 2013 meeting of the Oste-
oarthritis Research Society International (OARSI), pertaining to
advances in the epidemiology and treatment of OA.
Methods
The primary literature search was conducted using PubMed
(http://www.ncbi.nlm.nih.gov/pubmed/) with the search terms
“osteoarthritis [ti] AND treatment [All Fields]” and the following
limits activated: humans, English language, all adult 19þ years,
published between April 1 2013 and March 31 2014. This search
identiﬁed 113 articles. A secondary literature search was then
conducted with the search terms “osteoarthritis [ti] AND epide-
miology”, with the same limits; these searches identiﬁed a total of
122 articles. The titles of all articles were reviewed in order to reﬁne
the topic area and to identify major OA clinical research themes of
the past year. Studies selected for inclusion in the review presen-
tation were those deemed by the author to be of high quality with
potential to affect the management of OA in clinical practice.
Results
Theme 1: the interplay between OA & other chronic conditions
OA and risk for serious cardiovascular outcomes
Two studies examined the risk for CVD in people with OA.
Rahman et al.17 compared time to a composite CVD outcome
(hospital admission for myocardial infarction, ischemic heart dis-
ease, congestive heart failure or stroke) in 12,745 adults 20 years
with OA (cases) and no prior CVD history with up to three non-OA
matched controls (sex, age, year of ‘diagnosis’). Using health
administrative data, OA cases were those with at least two visits to
a health professional in 2 years separated by at least 1 day or 1
discharge from hospital with ICD-9 code of 715 or ICD-10 codes of
M15eM19. From a published abstract, the sensitivity & speciﬁcity
of this OA diagnosis algorithmwere 60e70%18. Over a mean follow-
up 13 years, the authors identiﬁed 7995 hospitalizations for CVD
events. Controlling for covariates (neighborhood income quintile,
body mass index (BMI), imputed using population data for age and
sex, chronic obstructive pulmonary disease (COPD), hypertension,
hyperlipidemia, diabetes, and Charlson score) in the ﬁnal multi-
variable Cox proportional hazards model, OA diagnosis was found
to be an independent predictor of CVD among: older men (Relative
Risk (RR) 1.15, 1.04e1.27); younger women (RR 1.26, 1.13e1.42);
older women (RR 1.17, 1.07e1.26); but not younger men (RR 1.08,
0.97e1.19).
A second study utilized data from an established population
cohort with moderate to severe hip and knee OA to examine the
relationship between baseline walking disability (Health Assess-
ment Questionnaire (HAQ) walking disability score 0e3) and risk
for a composite CVD outcome (hospitalization for angina, acute
myocardial infarction (AMI), coronary revascularization (coronary
artery bypass graft (CABG) or percutaneous coronary intervention
(PCI)), congestive heart failure (CHF), stroke or transient ischemic
attack (TIA))19. Over median 9.2 years, 38% of 2156 OA participants
experienced the CVD outcome. Controlling for socio-demographics,
CVD risk factors (BMI, smoking, diabetes, hypertension, non-ste-
roidal anti-inﬂammatory drug (NSAID) use) and additional health
problems, walking disability was a signiﬁcant independent pre-
dictor of CVD events with an adjusted Hazard Ratio (HR) per unitincrease in HAQ walking of 1.17 (1.08e1.27). Further adjustment for
post-baseline receipt of a primary, elective hip or knee joint
arthroplasty (TJA) did not attenuate this effect and found that TJA
was protective of CVD events (adjusted HR ¼ 0.66, 0.52e0.85,
P < 0.001). Interestingly, the effect of a HAQ walking score of 2 vs
0 on risk for CVD events was roughly equivalent to that associated
with a baseline diagnosis of diabetes.
Vascular abnormalities and OA
It has also been hypothesized is that circulatory disturbances
associated with CVD may impact the synovial membrane and sub-
chondral bone and contribute to cartilage destruction and OA20,21.
Using data from the Rotterdam study, Hoeven et al.22 examined the
relationship between atherosclerosis (carotid intima media thick-
ness and carotid plaque) with both the presence and progression of
knee, hip & hand OA (Kellgren-Lawrence (KL) grade on X-ray)
controlling for confounders (age, BMI, lipid levels, smoking, dia-
betes, and hypertension). They documented independent associa-
tions between these vascular abnormalities and OA of knee and
hand joint in women but not men, but found no association with
hip OA. The authors propose that their ﬁndings are consistent with
the greater perceived inﬂuence of systemic inﬂammation in knee vs
hip OA23,24.
Metabolic syndrome and OA
Jungmann et al.25 evaluated the association of metabolic risk
factors (abdominal circumference, hypertension, fat consumption,
and diabetes) with severity and 2-year progression of early
degenerative cartilage changes in the knee, evaluated using T2
relaxation times and magnetic resonance imaging (MRI), in 403
OsteoArthritis Initiative (OAI) participants. In cross-sectional ana-
lyses, the authors found that metabolic risk factors were signiﬁ-
cantly associated with higher T2 relaxation times, suggesting
increased cartilage degeneration may be caused by modiﬁable
metabolic disorders. No longitudinal relationships were found.
Diabetes and OA
Nieves-Plaza et al.26 asked: Is diabetes a risk factor for OA? In
their study, the prevalence of hip, knee, hand OA (deﬁned using
American College of Rheumatology classiﬁcation criteria) was
compared in Hispanics with vs without diabetes, and before and
after controlling for self-reported confounders (smoking, exercise,
socio-demographics, comorbidities, insulin use). In their fully
adjusted model, the likelihood that subjects met criteria for OAwas
signiﬁcantly higher among those with vs without diabetes
(adjusted Odds Ratio (OR) 2.18, 1.12e4.24). Further, within their
diabetes cases, the risk of OAwas ﬁve times greater in women than
men, and higher in those that were not using insulin. Given that
Insulin-like growth factor 1 (IGF-1) is known to be reduced in OA,
the latter ﬁnding is provocative, suggesting that growth factors may
preserve cartilage.
OA in the setting of other conditions
The impact of comorbidity on the treatment of OA has also been
evaluated in several studies over the past year. The 2014 OARSI non-
surgical knee OA treatment guidelines27 evaluated the evidence
supporting use of available therapies in four distinct knee OA pa-
tient subgroups e those with and without concomitant joint
complaints and with and without other chronic conditions (Fig. 1).
The guidelines highlight the paucity of evidence supporting the use
of therapies in the largest group of patients with knee OA, those
with comorbid conditions and multiple joint complaints, empha-
sizing the need more clinical trials in people with OA in setting of
other common chronic conditions.
Fig. 1. Appropriate treatments summary.
From: McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis.
Osteoarthritis Cartilage 2014;22:363e88.
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randomized trial evaluating the efﬁcacy of the 6-week Stanford
Arthritis Self-Management Program (ASMP), delivered in a
community-based setting. Subjects were adults referred to rheu-
matology or orthopedic surgery for hip or knee OA. The trial found
that uptake of the ASMP was low despite the absence of ﬁnancial
barriers to participation and ﬂexibility of times offered. Thus, the
current study examined factors limiting participation in self-
management based on data from recorded recruitment telephone
calls. Among the most frequently reported reasons for non-
participation was concurrent illness (OA is not the only problem)
and the appropriateness of an arthritis-speciﬁc vs generic chronic
disease self-management approach. Additional reasons for non-
participation included: disinterest; limited mobility (pain, fear of
falling, difﬁculty getting to the program); lack of endorsement of
the value of the program by their primary care physician; a desire
for pharmacotherapy or surgery; and a sense by the patient that
they were already coping well with their OA.
Cheraghi-Sohi et al.29 examined OA patients' health priority
setting when living with more than one chronic condition. The
authors re-analyzed four qualitative studies to examine how pa-
tients with OA prioritize OA relative to their other health problems.
Key ﬁndings of their study were as follows: patients have limited
time to address their health concerns; they tend to prioritize the
condition(s) that are perceived as ‘more severe’ or with worse
future implications; health priorities changed over time, inﬂuenced
by whether or not the condition was ‘under control’, which was, in
turn, inﬂuenced by themessages they received from physicians; OA
was seen as a priority when it impacted mobility for independence
or care-giving; and, ﬁnally, in an effort to balance health care issues,
the most frequently dropped activity was exercise.
Their ﬁndings are consistent with those of Wilkie et al.30 who
prospectively evaluated the impact of multi-morbidity on partici-
pation restriction in a cohort of 1053 peoplewho consulted primarycare for lower extremity OA. Thosewith participation restrictions at
baseline were excluded. Multi-morbidity was deﬁned based on
patient self report. Participants were asked to report the presence
of three common chronic health conditions (chest problems, heart
problems, diabetes), two impairments most commonly associated
with disability (deafness and eyesight problems) and seven other
impairments (falls, memory, cough with spit, breathless with
walking, dizziness, weakness in arms/legs, elevated blood pres-
sure); a count of health conditions and impairments was calculated
(0e12) and multi-morbidity was deﬁned as a score > the median
value of 2 (i.e., 3þ vs 0e2). Path analysis was used to determine the
relationship between baseline multi-morbidity & incident partici-
pation restrictions at 3 years. Additional variables of interest were
joint pain severity, obesity, locomotor disability, and depression.
Analyses found that multi-morbidity contributed to the develop-
ment of participation restrictions at 3 years through its effects on
locomotor disability and depression.
Theme 2: targeted treatment in OA (personalized medicine)
Predictors of response to intra-articular injection of corticosteroids
in knee OA
Maricar et al.31 conducted a systematic review of the predictors
of response to intra-articular injection of corticosteroids in subjects
with knee OA. Eleven publications met their eligibility criteria and
were included in their review. The studies weremainly small in size
with substantial variability in the predictors of response studied,
and in how these predictors were deﬁned. Thus, the authors were
unable to pool the studies. From the individual studies, they found
inconsistent evidence that likelihood of response to intra-articular
steroid injection in knee OA is greater if: there is evidence of
inﬂammation (synovitis, effusion, ﬂuid withdrawal); OA symptoms
are more severe; and ultrasound is used to guide the injection. The
authors conclude that larger, higher quality studies are needed.
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Given the role of systemic inﬂammation in the pathogenesis of
OA, immunomodulating agents are increasing being investigated as
treatment options in OA. Wenham et al.32 conducted a pilot open
label study of methotrexate (MTX) in 30 knee OA patients with
demonstrated synovitis (ultrasound conﬁrmed effusion and syno-
vial thickening) and whowere intolerant of other OA therapies. The
mean age of participants was 64.5 years, with a mean pain visual
analog scale (VAS) score of 6.8/10. MTXwas prescribed up to 20mg/
week for 24 weeks. Thirteen of the 30 patients achieved the OARSI
responder criteria, but no relationship was found between pain
response and change in synovitis on ultrasound. A potential
explanation for the ﬁndings posed by the authors is that ultrasound
may be an insensitive measure of treatment effect on the synovium
(e.g., evaluates thickness but not cellularity) and cannot assess
other aspects of OA structural damage, including bone marrow le-
sions and bone attrition. A randomized trial is currently underway
using MRI to evaluate the structural impact, if any, of treatment of
OA with MTX.
Pain sensitization and prediction of pain outcomes after joint
replacement
Approximately 20% of patients experience severe chronic pain
after knee replacement33. Wylde and colleagues hypothesized34
that non-response to knee replacement may be greater in those
patients with vs without pain sensitization? If so, targeted treat-
ment of pain sensitization prior to surgerymay reduce adverse pain
outcomes. Using quantitative sensory testing (QST), they examined
the relationship between pre-operative pain thresholds and the
presence of persistent pain (Western Ontario and McMaster Uni-
versities Osteoarthritis Index (WOMAC) pain scale score) 1 year
after total knee replacement (TKR) in 51 OA patients. Among their
study subjects, 15 (29%) met their criteria for ‘persistent pain’.
Those with lower pre-operative pressure pain thresholds at the
forearm (indicating greater widespread pain sensitization) re-
ported more severe pain in the replaced knee 1 year after surgery.
Larger studies are now underway to conﬁrm these ﬁndings.
Conclusions
The past year has seen an enhanced focus by OA clinical re-
searchers on understanding the inﬂuence of systemic inﬂammation
on OA phenotype, management, and outcomes, and on elucidating
the characteristics of subgroups of patients with OA who are more
or less likely to respond to speciﬁc therapies (i.e., personalizing
management approach). Results from these studies highlight the
high prevalence of comorbidities among people living with
symptomatic OA and the interplay of these conditions with OA on
chronic disease management and outcomes. This body of research
indicates an urgent need for clinical trials of interventions in OA
that take into consideration the heterogeneity of OA as a condition.
Speciﬁcally, careful characterization of OA patients e at the joint
and systemic levels e and consideration of the potential in-
teractions between treatments and these OA characteristics are
needed. Finally, given the high prevalence of other common age-
and obesity-related conditions in people living with OA, additional
research is warranted to promote evidence-based practice for the
treatment of OA in the setting of other common chronic conditions.
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